key: cord-0879214-0hnxpjq7
authors: Hernandez Acosta, R. Alfonso; Garrigos, Zerelda Esquer; Marcelin, Jasmine R.; Vijayvargiya, Prakhar
title: COVID-19: Pathogenesis and Clinical Manifestations
date: 2022-02-01
journal: Infect Dis Clin North Am
DOI: 10.1016/j.idc.2022.01.003
sha: 7ec200de128b62f21936a12651069b287a358bd1
doc_id: 879214
cord_uid: 0hnxpjq7

In this review, we summarize the current knowledge about the virology, the host-pathogen interactions and mechanisms of disease of coronavirus disease 2019 (COVID-19) in humans. We also describe the various clinical presentations of the disease and the underlying mechanisms of disease on the respiratory system and other organs which originate them.

Betacoronavirus genus (which also includes severe acute respiratory syndrome coronavirus 1 [SARS] and Middle East respiratory syndrome-related coronavirus [MERS] ) which are large positive-sense single-stranded RNA viruses (estimated size 70-200nm) with zoonotic origins and transmissible from person to person. Coronaviruses are named after the projections from their membrane (Corona, lat. "crown"). 1 When it was first described, the virus had been named 2019-novel coronavirus (2019-n-CoV.) but renamed SARS-CoV-2 due to a higher similarity with SARS-CoV than initially thought. Since its emergence in late 2019 with the first cases described in Wuhan, China, its human-to-human transmission is clear, with uncounted active infections and millions of deaths worldwide. Furthermore, airborne spread 2 and transmission by asymptomatic individuals 3 further add to its potential for infection.

Global collaboration and sequencing technologies have helped uncover the pathogenic mechanisms behind SARS-CoV-2 infection and its associated clinical manifestations, collectively called coronavirus disease 2019 . Nevertheless, COVID-19 remains a novel disease and its complete pathogenesis is yet to be elucidated. Several studies have been conducted to better understand the host-virus interaction and pathogenesis to develop strategies for prevention and treatment. Insight from previous infections caused by coronaviruses such as SARS and MERS has also been useful to understand the pathogenesis of this new virus. Even though several promising new (and repurposed) treatments are being studied, there is yet to be a clear and effective treatment modality. The development of effective vaccines as part of J o u r n a l P r e -p r o o f preventive strategies has also played a significant role in controlling this pandemic 4 . In this article, we review clinical and experimental evidence available for pathogenesis of and highlight various clinical presentations in human infection.

Coronaviruses have the largest RNA viral genomes ranging from 26,000 to 32,000 bases 5 and the genome is made up almost entirely of protein coding sequences. 6 SARS-CoV-2 is the seventh known coronavirus capable of causing human infection. 7 Whole genome sequencing revealed that SARS-CoV-2 has genomic similarities to be placed in the same Betacoronavirus clade like SARS-CoV, MERS-CoV and SARS-like bat CoV, however, phylogenetic analysis and amino acid sequences have revealed enough differences in SARS-CoV-2 to confer structural and functional difference from other coronaviruses. 8 The genome of SARS-CoV-2 is about 29.9 kB 9 in length (in contrast, SARS-CoV is about 29.7 kB long 10 ) of which about 79-82% includes a sequence 11 homology to SARS-CoV and 50% to MERS-CoV 8 . Unlike SARS-CoV, SARS-CoV-2 possesses a distinguishing polybasic cleavage site (RRAR) that is cleaved by furin and other proteases. Presence of this furin-cleavage site has been suggested to confer SARS-CoV-2 with higher transmissibility than SARS-CoV and enhance its virulence. 12 Like SARS-CoV and other coronaviruses, SARS-CoV-2 codes for four structural proteins: spike (S), membrane (M), envelope (E), and nucleocapsid (N). The viral envelope is created by S, E and M protein together while the N protein binds to the viral RNA. 13 Origin & transmission J o u r n a l P r e -p r o o f Coronaviruses are diverse and pathogenic to a variety of animals, including pigs, cows, dogs, cats and chickens. Bats act as a reservoir for coronaviruses, including SARS-CoV-2 6 . When the first cases of pneumonia were described in the Hubei province in China in late 2019, genome sequencing and phylogenetic analysis identified the pathogen as a novel coronavirus with bat and pangolin genetic sequences, further adding evidence to a zoonotic origin of the virus. 14

Infection occurs when the viral particles are inhaled, enter the airways, and bind to the receptors on host cell surface. Like other coronaviruses, SARS-CoV-2's spike (S) protein binds to angiotensin-converting enzyme 2 (ACE2), a metalloproteinase found in large amounts in airway epithelial and endothelial cells that undergoes a conformational change to permit the fusion of viral and host cell membranes. 15 While this mechanism is shared by SARS-CoV, a recent study using biophysical assays found that the spike protein of SARS-CoV-2 binds 10-20 times more strongly to ACE2 16 . The higher binding affinity to ACE2 has been proposed to be responsible for increased viral transmissibility and severity of disease compared with SARS-CoV.

The S protein is composed of two subunits: S1 and S2 17 . When the S1 subunit attaches to the ACE2 receptor on the host cell, a transmembrane protease, serine 2 (TMPRSS2) cleaves the S protein to reveal S2 subunit, and ACE2. The spike protein undergoes dramatic conformational changes leading to fusion of viral membrane with host cell. The viral particle is then engulfed in an endosome. The virion escapes the endosome when it is cleaved by a host J o u r n a l P r e -p r o o f cell protease, cathepsin, or by drop in pH (acidification) 18 . Cathepsin has been proposed as a therapeutic target to prevent infection with SARS-CoV-2 19 .

High expression of ACE2 on the surface of lung alveolar epithelium and enterocytes of the small intestine was proposed to contribute to the viral entry of SARS-CoV, a mechanism that SARS-CoV-2 likely mirrors 20 . Besides these locations, ACE2 is widely expressed in various human tissues including heart, kidneys, and arterial and venous endothelial cells. Presence of ACE2 in these tissues likely contributes to extra pulmonary manifestations such as diarrhea, acute renal injury, cardiac injury, and vascular endothelial damage with multi-system organ failure 21 . Children have lower ACE2 expression which might explain lower early COVID-19 acquisition rates in children but higher rate of multisystem inflammatory syndrome (MIS-C) in older children. The tissues expressing ACE2 do not participate equally in pathogenesis of COVID-19, suggesting other factors are involved in contributing to tissue damage 22 .

Early after the discovery of SARS-CoV-2, COVID-19 infection was described in two phases: a viral response phase and a host inflammatory response phase (also referred to as cytokine storm phase) [ Figure 1 ]. This general principle has remained relevant over time but 

The innate immune response is activated when pathogen-associated molecular patterns (PAMPs) are recognized by host receptors 24 . PAMPs are small molecules such as lipopolysaccharides, peptidoglycan, lipoteichoic acid, nucleic acids and other molecules that are present in different patterns and trigger immune cascades when recognized by the host. The protein receptors in the host responsible for detecting PAMPs are called pattern recognition receptors (PRRs). These PRR include toll-like receptors (TLRs), C-type lectin receptors (CLRs), NOD-like receptors (NLRs) and RIG-I-like receptors (RLRs). Once activated these receptors initiate downstream signaling pathways leading to secretion of type I and type III interferons, and assembly and activation of NLRP3 inflammasome and other inflammasome complexes that promote secretion of proinflammatory cytokines including interleukin 1β (IL-1β) and interleukin 18 (IL-18) 25 . Activation of antigen presenting cells by pro-inflammatory cytokines also recruits the adaptive immunity to enhance viral clearance by antibody-mediated neutralization and T-cell mediated cytotoxicity 24 . The inflammasome pathway triggers the coagulation cascade, contributing to coagulopathy and the thrombotic events seen in severe COVID- 19. 26 Like PAMPs, host cells are also activated by damaged or stressed cells in the setting of inflammation 24 , necrosis or hypoxia even if no microbial PAMPs are present. These are called damage-associated molecular patterns (DAMPs). While activated PAMP and DAMP pathways contribute to viral clearance, an overactivated response leads to a dysregulated immune system and exacerbates inflammation and damage through a cytokine storm 26 [ Figure 3 ]. These pathways have been described for viral infections in the past, but corresponding pathways specific to SARS-CoV-2 remain to be identified.

One pro-inflammatory cytokine, interleukin 6 (IL-6) garnered attention after reports of ARDS became common in patients with severe COVID-19. IL-6 is a mediator of both innate and adaptive immune responses and acts as both proinflammatory cytokine and anti-inflammatory myokine. IL-6 is secreted by macrophages when PAMPs binds to PRRs. Elevated IL-6 was reported to be associated with poor prognosis and consequently, much emphasis was placed on treatment of severe COVID-19 with IL-6 receptor antagonists 4 . Clinical trials have suggested there is some benefit to limiting hyperactive immune responses through blocking IL-6 in severe COVID-19 27 .

An early innate immune response is critical in activating T and B cell immune system and terminating the infection at asymptomatic or mild to moderate stage 28 . A delayed or absent innate immune response, either by immune evasion by the virus or defective host immunity (or J o u r n a l P r e -p r o o f both), fails to prime the adaptive immune system and contributes to high risk of severe or fatal COVID-19.

Antigen-presenting cells are the initial component of antiviral response by the host. The specific mechanism of antigen presentation of SARS-CoV-2 is not well understood, however some of it can be extrapolated based on data from other betacoronaviruses, which mainly depends on MHC I (major histocompatibility complex-1) molecules. Several HLA types have been associated with increased susceptibility or protection against SARS-CoV. 29 It is highly likely there exist HLA alleles that predict increased susceptibility to SARS-CoV-2 and correlate with more severe outcomes, although research in diverse populations is ongoing.

Both humoral and cellular immune response is activated by antigen presenting cells as J o u r n a l P r e -p r o o f While long-term memory immunity is not yet clarified for SARS-CoV-2, it is known that CD4 and CD8 memory T-cells persist for years after recovery from SARS-CoV infection and can respond to SARS-CoV antigens even after six years. On the other hand, it seems that memory Bcell response is almost absent after 6 years after recovery from SARS 35 . In follow-up of early SARS-CoV-2 infections and following vaccination, it also seems clear that T cell responses are longer than antibody responses. Longer-term follow up will be required to fully elucidate the duration of post-infection responses.

It is believed that SARS-CoV-2 uses similar mechanisms to evade the host's immune response as other coronaviruses. Viral proteins interfere with function and maturation of antigen-presenting cells and activate pathways that decrease transcription and transport of antiviral proteins (such as interferons). Antigenic variation, particularly in M protein, also decreases production of interferons. 36 Another mechanism of immune evasion of particular concern is Spike protein mutations, which alter the ultrastructure and function of the epitope domain, impairing function of antibodies against the immunodominant protein 37 . These mutations in structural proteins have caused (and will continue to cause) the emergence of different variants of SARS-CoV-2. SARS-CoV-2 has undergone significant mutations, with some lineages emerging as variants of concern (VOC) as defined by the World Health Organization. These variants are so named because of their potential for higher transmissibility, more severe disease, or high risk of immune escape.

Chapter X: Virology describes variants and viral mutation in greater depth. have been disproportionately higher than other racial or ethnic groups. The role of biology and disproportionate prevalence of medical comorbidities has not been enough to explain these inequities, in addition to a wealth of data suggesting that these differences are driven by social and structural vulnerabilities resulting from the impacts of structural racism in these communities 43, 44 . Additional details of inequities seen with COVID-19 will be presented later in this collection (Chapter 4). The incubation period following exposure to SARS-CoV-2 has been estimated anywhere between two and fourteen days, and varies by VOC. In a pooled analysis of 181 confirmed COVID-19 cases from China the median incubation period was estimated to be 5.1 days (95% CI, J o u r n a l P r e -p r o o f 4.5 to 5.8 days) 46 . Noteworthy, compared to earlier variants of concern, shorter incubation periods have been documented in infections with Delta and Omicron variants, with median incubation period of four days 47 .

Asymptomatic infections involve individuals who test positive for SARS-CoV-2 but have no symptoms. It is estimated that 50% of persons who test positive for SARS-CoV-2 are asymptomatic at the time of diagnosis 3 . The overall proportion of asymptomatic infections was estimated around 25% in one meta-analysis, but the proportion of asymptomatic infections is generally higher in persons with pre-existing immunity 48 .

Asymptomatic infections are more common in young and middle-aged patients (<50 years of age), women, and individuals without underlying comorbid conditions 49 . In an early study including 55 cases of asymptomatic infection 50 51 . Gastrointestinal symptoms such as diarrhea, nausea/emesis have also been reported, but with lower frequencies (<20%) than in SARS or MERS infections 52 . The incidence of symptoms such as loss of smell or taste varies significantly among studies, with frequencies between 10% and 40% 23 . Loss of taste or smell (anosmia and ageusia) however, are often recognized by patients as a hallmark, or pathognomonic feature of COVID-19, and frequently precede the onset of other flu-like symptoms. This peculiar manifestation has been studied, with one of the proposed theories being that the specialized cells in the olfactory bulb and olfactory epithelium have the ACE2 receptors for viral entry and subsequent infection, although there are detectable changes in brain imaging in some persons with anosmia 53 54 .

Most patients recover over the course of a few weeks; however, persistent anosmia and ageusia is also frequently described and is still under study.

Patients with moderate disease have evidence of lower respiratory disease on physical exam or chest imaging but maintain an oxygen saturation of equal or >94% on room air at sea level 45 . Individuals with severe disease have oxygen saturation on room air below 94% at sea level, a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) <300 mm Hg, or a respiratory rate >30 breaths/min, or lung infiltrates >50% 45 . Critical disease is defined as respiratory failure, septic shock and/or multiorgan failure 45 .

During the initial phase of the pandemic, severe disease accounted for up to 14% of cases while critical illness was seen in about 5% of cases according to the Chinese Center for Disease Control and Prevention 55 . The rate of severe disease, however, varies depending on several factors including history of prior infection, vaccination status, variant causing the infection and available healthcare resources. For example, Omicron variant appears to be associated with milder disease compared to Delta variant 56 . The risk of progression to severe and critical disease is markedly decreased in persons with prior immunity, especially after vaccination.

The hallmark of COVID-19 is respiratory disease, which is the consequence of severe inflammation and damage of lung tissue. The pathogenesis of COVID-19 is still being extensively studied. The replication of the virus inside the respiratory epithelium causes a proinflammatory state through the production of chemokines and cytokines, including IL-1, IL-6 and TNF-a, among many others 57 . The main mechanism of lung injury in COVID-19 is diffuse alveolar damage 56 . Damage to endothelium mediated by fibrin and inflammation causes edema and thrombosis of lung vessels. This can cause extensive injury and edema of the alveoli with formation of protein deposits and hyaline membranes. This inflammation in the lung parenchyma manifests as mucus production, cough, and dyspnea. On imaging, patchy opacities can be seen on X-ray or ground-glass opacities on CT. These opacities are usually of peripheral / subpleural distribution bilaterally. Pneumonia can be significant enough to cause hypoxemic respiratory failure, and in some cases may progress to acute respiratory distress syndrome (ARDS), and ultimately, death. Risk factors for progression to ARDS have been identified: age J o u r n a l P r e -p r o o f >65 years, diabetes mellitus, hypertension, and obesity, and non-receipt of SARS-CoV-2 vaccination, among others 58 .

ARDS is a clinical entity that presents with bilateral pulmonary infiltrates and severe hypoxemia, which results from extensive damage and edema of the alveolar system due to 

Dizziness and headache are among the most common neurologic symptoms reported in the literature, although the prevalence 64 . A minority of patients with severe COVID-19 can present with acute encephalopathy, cerebrovascular accidents, changes in vision, seizures and radiculopathy 65 . So-called "brain fog" has also been described, particularly as a sequela of COVID, referring to a nonspecific and subjective inability to concentrate or to perform certain tasks. One of the proposed mechanisms is direct viral interference in mitochondrial function in neurons, although studies are ongoing. 66 The prevalence of ischemic stroke in patients with COVID-19 has been estimated to be around 5%, and it carries a high mortality of 30-40% 67 . It is most commonly seen in patients above 70 years of age, but it has also been reported in younger, previously healthy patients 68 Of note, the composition of these microthrombi was different from that of patients without COVID-19. Myocarditis associated with COVID-19 has also been described. The risk of myocarditis in people with COVID-19 is approximately 16 times that of people without COVID-19, and the highest risk is found in children <16 years and elderly >75 years 71 . While there has been concern about infrequent cases of myocarditis associated with SARS-CoV-2 vaccination, the risk of myocarditis due to COVID-19 itself is 4 to 40-fold higher than from vaccination with one of the mRNA vaccines 71 72 . 

Venous thromboembolism, consisting of deep venous thrombosis (DVT) and pulmonary embolism (PE) is a common complication of hospitalized patients with COVID-19, and less frequently in persons whose COVID-19 respiratory infection is not severe enough to merit hospitalization. The prevalence has been identified to be particularly high in patients admitted to the ICU (from 50-80% depending on the series 77,78 ), even when the clinical suspicion may be low 73 . However, patients that are admitted to acute care units also have an increased risk of DVT (20-30% of patients) 79 . These thrombotic events can happen despite pharmacological prophylactic doses of anticoagulant 79 . PE is another potentially life-threatening complication J o u r n a l P r e -p r o o f that is more prevalent in patients with COVID-19, particularly those admitted to the ICU (20-30%). Persons admitted to acute care for COVID-19 have PE rates of 10-20% 79, 80 . DVT can be seen both in lower and upper extremities, and presents identically to non-COVID-associated VTE, subclinical and asymptomatic presentations. The diagnosis of PE in patients who are mechanically ventilated may be challenging, especially given the many reasons for physiologic shunt present due to microthrombi, airspace disease from COVID-19 pneumonia and superimposed bacterial or fungal infection, and ARDS. The preferred diagnostic modality is CT angiography.

Thrombotic complications in arterial vessels have also been described. Acute limb ischemia has been observed in COVID-19 patients, regardless of preexisting peripheral arterial disease 73 . Arterial thrombosis manifests as severe pain and discoloration of an extremity, cold and clammy extremities, and decreased pulses. Thrombosis of the thoracic or abdominal aorta has also been reported, manifesting as unilateral limb ischemia, bilateral loss of pulses in the lower extremities, bilateral loss of sensation or acute periumbilical/epigastric pain 81 .

Mesenteric ischemia can present with diarrhea and severe abdominal pain 82 . Arterial thrombotic complications often cause a marked elevation of D-dimer as well as inflammatory markers such as CRP, although these markers are often drastically elevated in persons with severe or critical COVID-19, and the difficulty making these diagnoses can result in delays in detection, and further increase their morbidity and mortality.

J o u r n a l P r e -p r o o f COVID-19 is a disease that has been proven to affect children of all ages, especially as the incidence of pediatric COVID-19 increased during infection waves attributable to the delta and omicron variants. The most common clinical presentation in children is fever with cough, similar to adult infections. Many infections are asymptomatic, and in the majority, disease is mild or moderate. Children younger than 1 year old may have a higher incidence of critical disease and GI symptoms 83 .

In May 2020, the CDC reported a severe inflammatory syndrome that presented in otherwise healthy children that had features similar to Kawasaki disease, with persistent fever, rash and other various neurological, gastrointestinal, dermatological, cardiac and renal manifestations 84 

Post-acute sequelae of COVID-19 (PASC), also colloquially termed "Long COVID" or "long-haul COVID-19" is a clinical entity that has gained recognition as the pandemic continued into its second year in 2021. While there is no consensus for a single definition, in general, PASC refers to the persistence of symptoms for more than three months after the onset of symptoms 85 . The most common reported symptoms are shortness of breath and fatigue, however an extensive list of symptoms involving multiple systems has been described. These symptoms include cognitive dysfunction ("brain fog"), mental disorders (depression, anxiety), J o u r n a l P r e -p r o o f headache, musculoskeletal complaints (myalgia, joint pain, chest wall pain), taste and smell disorders, chronic cough, alopecia, insomnia, among many others 86 . Further details on pathophysiology, manifestations, and proposed treatments for PASC are discussed in Chapter 9

Post -Acute Sequelae of COVID-19.

COVID-19 is a disease that affects multiple organ systems, and the prevailing theory is that most symptoms outside of the upper respiratory tract are predominately triggered by an exaggerated inflammatory response in the host. This inflammatory process results in a wide variety of clinical presentations, ranging from asymptomatic to severe multiorgan dysfunction.

COVID-19 affects people of all age groups, including children, who also suffer from severe disease. Groups of people with poor access to healthcare such as Black and Hispanic/Latino communities have been disproportionately impacted by COVID-19, fueling increased awareness of healthcare disparities. Furthermore, the persistence of symptoms in people who recover from COVID-19 adds to its morbidity and impact on the workforce, mental health, and economic impacts in the long-term. The complete pathogenesis of SARS-CoV-2 is slowly being unraveled through knowledge from similar respiratory viruses as well as a rapid proliferation of research on this novel pathogen. Fully understanding the pathogenesis, especially of extrapulmonary manifestations of COVID-19 disease, will likely remain an area of developing knowledge for years to come.

 COVID-19 can range from asymptomatic infection to severe multiorgan failure. The hallmark of the disease is exaggerated inflammation in the lung tissue that can progress to ARDS, although it also causes significant endothelial damage and thrombosis in other systems.  COVID-19 affects different organs and systems, and the presentation depends on the organ systems affected. Not all patients present with respiratory symptoms.  While venous thrombosis is widely reported in COVID-19, arterial thrombosis can also be encountered as mesenteric or aortic thrombosis as well as acute limb ischemia. These often cause significant elevations of D-dimer and C-reactive protein (CRP).  While COVID-19 is generally less severe in children than in adults, it can present with persistent fever, rash and multiorgan dysfunction (MIS-C) that often requires ICU level of care.  Post-acute sequelae of COVID-19 (also known as "long COVID") is generally defined as persistent symptoms for more than 3 months after the initial onset of symptoms of COVID-19. 

Coronavirus Transcription: A Perspective

Airborne transmission of COVID-19 and the role of face mask to prevent it: a systematic review and meta-analysis

Treatment Considerations for COVID-19: A Critical Review of the Evidence (or Lack Thereof)

Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study

On the origin and evolution of SARS-CoV-2

A Novel Coronavirus from Patients with Pneumonia in China

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet

The Genome Sequence of the SARS-Associated Coronavirus

Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan

Characteristics of SARS-CoV-2 and COVID-19

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Possible Bat Origin of Severe Acute Respiratory Syndrome Coronavirus 2

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19

Coronaviruses -a general introduction -CEBM

Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup

Is multisystem inflammatory syndrome related with coronavirus disease 2019, Kawasaki disease, and angiotensin-converting enzyme 2 in children?

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet

Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients

Adaptive immunity to SARS-CoV-2 and COVID-19

Epidemiological and Genetic Correlates of Severe Acute Respiratory Syndrome Coronavirus Infection in the Hospital with the Highest Nosocomial Infection Rate in Taiwan in 2003

Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity

Comprehensive mapping of immune perturbations associated with severe COVID-19

Viral and Antibody Kinetics of COVID-19 Patients with Different Disease Severities in Acute and Convalescent Phases: A 6-Month Follow-Up Study

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Lack of Peripheral Memory B Cell Responses in Recovered Patients with Severe Acute Respiratory Syndrome: A Six-Year Follow-Up Study

Innate immune evasion by SARS-CoV-2: Comparison with SARS-CoV

SARS-CoV-2 variants, spike mutations and immune escape

Association of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality: A systematic review and metaanalysis

Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: A systematic review and meta-analysis

Racial Disparity of Coronavirus Disease 2019 in African American Communities

Pandemic: Disparate Health Impact on the Hispanic/Latinx Population in the United States

COVID-19 Mortality Among American Indian and Alaska Native Persons -14 States

Addressing and Inspiring Vaccine Confidence in Black, Indigenous, and People of Color During the Coronavirus Disease

The Incubation Period of Coronavirus Disease

From Publicly Reported Confirmed Cases: Estimation and Application

Transmission, viral kinetics and clinical characteristics of the emergent SARS-CoV-2 Delta VOC in Guangzhou

Asymptomatic SARS-CoV-2 Carriers: A Systematic Review and Meta-Analysis. Front Public Health

CT imaging and clinical course of asymptomatic cases with COVID-19 pneumonia at admission in Wuhan

Clinical Outcomes in 55 Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Who Were Asymptomatic at Hospital Admission in Shenzhen

Coronavirus Disease 2019 Case Surveillance -United States

Focus on Middle East respiratory syndrome coronavirus (MERS-CoV)

Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia

Olfactory Bulb MRI and Paranasal Sinus CT Findings in Persistent COVID-19 Anosmia

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

Comparison of outcomes from COVID infection in pediatric and adult patients before and after the emergence of Omicron. medRxiv

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

Acute Respiratory Distress Syndrome

COVID-19 acute respiratory distress syndrome (ARDS): clinical features and differences from typical pre-COVID-19 ARDS

Invasive Pulmonary Aspergillosis in Patients with SARS-CoV-2 Infection: A Systematic Review of the Literature

Skin Manifestations Associated with COVID-19: Current Knowledge and Future Perspectives

Neurologic complications of COVID-19

Encephalitis as a clinical manifestation of COVID-19

Selective Neuronal Mitochondrial Targeting in SARS-CoV-2 Infection Affects Cognitive Processes to Induce "Brain Fog" and Results in Behavioral Changes that Favor Viral Survival

Management of acute ischemic stroke in patients with COVID-19 infection: Report of an international panel

Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young

COVID-19 and cardiac injury: clinical manifestations, biomarkers, mechanisms, diagnosis, treatment, and follow up

Microthrombi as a Major Cause of Cardiac Injury in COVID-19: A Pathologic Study

Association Between COVID-19 and Myocarditis Using Hospital-Based Administrative Data -United States

Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection

Thrombotic complications of COVID-19

The Role of Inflammation in Venous Thromboembolism

Immunity, endothelial injury and complement-induced coagulopathy in COVID-19

Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans

Assessing the Risk for Development of Deep Vein Thrombosis among Chinese Patients using the 2010 Caprini Risk Assessment Model: A Prospective Multicenter Study

Venous Thrombosis Among Critically Ill Patients With Coronavirus Disease 2019 (COVID-19)

Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors

Acute Pulmonary Embolism Associated with COVID-19 Pneumonia Detected with Pulmonary CT Angiography

Severe arterial thrombosis associated with Covid-19 infection

Arterial Mesenteric Thrombosis as a Complication of SARS-CoV-2 Infection

A systematic review and meta-analysis of children with Coronavirus Disease 2019 (COVID-19)

Multisystem Inflammatory Syndrome (MIS)

Post-Acute Sequelae of SARS-CoV-2 Infection Among Adults Aged ≥18 Years

Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments